The Editorial Executive Committee welcomes letters, which should be less than 250 words. Before a decision to publish is made, letters which refer to a published article may be sent to the author for a response. Any letter may be sent to an expert for comment. When letters are published, they are usually accompanied in the same issue by their responses or comments. The Committee screens out discourteous, inaccurate or libellous statements. The letters are sub-edited before publication. Authors are required to declare any conflicts of interest. The Committee's decision on publication is final.


Letter to the editor

Editor, – We write to take issue with the article 'Gabapentin documents raise concerns about off-label promotion and prescribing' (Aust Prescr 2003;26:18-9) and the associated editorial comment. Statements in the article are unfounded and are not relevant to the promotion of gabapentin by Pfizer in Australia, which has always been in accordance with the terms of its registration and the Medicines Australia Code of Conduct.

The use of gabapentin for the treatment of neuropathic pain was approved by the Therapeutic Goods Administration (TGA) in 2000. It is therefore not surprising, as the author notes, that there is an 'increasing use' of this drug for this purpose. Use of a simple comparison of sales trends for gabapentin, lamotrigine and vigabatrin to argue that gabapentin is being promoted in appropriately is misleading. Lamotrigine is subject to a boxed safety warning, and concerns about well-documented adverse effects on visual fields may have directed prescribers away from vigabatrin.

The Cochrane Collaboration1 may have found 'surprisingly few trials' supporting anticonvulsant use in the treatment of chronic pain. However, the two studies involving gabapentin2,3were pivotal in nature and provided the basis for the TGA's approval after evaluation. Three subsequent randomised controlled studies4,5,6-the last an independent study not sponsored by the manufacturer - have confirmed the effectiveness of gabapentin in the treatment of neuropathic pain in a wide range of diseases. In light of this, it would be more accurate to say that there is scant evidence of anticonvulsants, other than gabapentin (i.e. conventional anticonvulsants), being effective in chronic pain.

In summary, gabapentin has now been shown in five well-designed and published studies of 1095 patients to be effective and acceptably safe for the treatment of neuropathic pain.

While not promoting the use of gabapentin in unapproved indications, Pfizer maintains the right to respond in a professional and balanced manner to doctors' questions about unregistered uses of gabapentin or any other product, allowing doctors to observe the 'extra imperative to carefully weigh the potential benefits and harms involved, and to ensure these are openly canvassed, where possible and appropriate, with patients and their families'.7 It is then the doctor's prerogative to decide whether gabapentin should be used in such conditions.

William Lam
Medical Director, Neurosciences
Medical Department
Pfizer Australia
West Ryde, NSW


William Lam

Medical Director, Neurosciences Medical Department Pfizer Australia West Ryde, NSW